Skip to content

Biohaven BHVN Operating Income

Operating Income at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.33M-54.4%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$24.22M+10.7%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$132.29M+5.2%
uniQure logo
uniQureQURE
-$45.72M-16.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$3.65M+81.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%

Other financials

Income statement

See full
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's operating income?
Biohaven (BHVN) reported operating income of -$130.43M in Q1 2026.
How has Biohaven's operating income changed year-over-year?
Biohaven's operating income increased by 41.1% year-over-year, from -$221.56M to -$130.43M.
What is the long-term trend for Biohaven's operating income?
Over 3 years (2022 to 2025), Biohaven's operating income has grown at a 9.5% compound annual growth rate (CAGR), from -$567.93M to -$745.38M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.